Treatment options for Thymic carcinoma / thymoma mapped across 4 countries — covering cell therapy, chemotherapy, clinical trials and immunotherapy — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedSolid tumorLast checked June 2026
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
Japan
Lenvatinib mesylate (Lenvima)[1]ApprovedNo biomarker requirement stated in fetched Japan approval news release; Unresectable thymic carcinoma; supporting REMORA context involved advanced/metastatic thymic carcinoma after at least one prior platinum-based regimen. · Company/regulatory news release is not a PMDA label page; exact PMDA label, reimbursement, and current local access should be checked. No claim made for thymoma or for countries outside Japan. Confidence/conflicts: Medium-high for Japan approval announcement; exact PMDA label source remains a follow-up gap.
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked June 2026.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumabClinical trial · NCT05832827Clinical trialTrial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor contextClinical trial · NCT02623127Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
Is the tumor thymoma, B3 thymoma, or thymic carcinoma?
Is the disease resectable, borderline resectable, inoperable, metastatic, or recurrent?
Are systemic options being used as standard chemotherapy, off-label targeted therapy, or clinical trial treatment?
Is the diagnosis unresectable thymic carcinoma rather than thymoma?